MedTech

  • Advising Titan Medical Inc., a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery in its US$28.75 million public offering, as well as its Common Share Purchase Agreement of up to US$35 million.
  • Acting as corporate and securities counsel to a number of exchange-listed and privately held issuers engaged in pharma R&D and medical device development.
  • Advising on the development of global policies and Canadian corporate compliance policies on interactions with health professionals, reflecting the requirements of federal and provincial laws, regulations and industry codes of conduct (including the Innovative Medicines Canada Code of Ethical Practices, MedTech, Code of Conduct on Interactions with Health Professionals), provincial health profession laws and regulations, advertising laws and government requirements arising from registered vendor agreements.
  • Advising on market-access issues, including product and establishment licensing and obtaining registered vendor status with provincially-funded assistive device programs.
  • Representing medical device manufacturer in claims involving design manufacturing, and marketing defects.
  • Advising Desjardins Capital Markets, as lead underwriter, in Savaria Corporation’s C$70.75 million bought deal private placement, a TSX-listed leader in the accessibility industry.
  • Advising Titan Medical Inc., a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery in its US$28.75 million public offering, as well as its Common Share Purchase Agreement of up to US$35 million.
  • Acting as corporate and securities counsel to a number of exchange-listed and privately held issuers engaged in pharma R&D and medical device development.
  • Advising on the development of global policies and Canadian corporate compliance policies on interactions with health professionals, reflecting the requirements of federal and provincial laws, regulations and industry codes of conduct (including the Innovative Medicines Canada Code of Ethical Practices, MedTech, Code of Conduct on Interactions with Health Professionals), provincial health profession laws and regulations, advertising laws and government requirements arising from registered vendor agreements.
  • Advising on market-access issues, including product and establishment licensing and obtaining registered vendor status with provincially-funded assistive device programs.
  • Representing medical device manufacturer in claims involving design manufacturing, and marketing defects.
  • Advising Desjardins Capital Markets, as lead underwriter, in Savaria Corporation’s C$70.75 million bought deal private placement, a TSX-listed leader in the accessibility industry.

Key Contacts

Stay Up to Date

Subscribe to receive our insights and perspectives on the latest legal developments that will affect you.
Register